Platzbecker, Uwe

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia

Acute Myeloid Leukemia ResearchHistiocytic Disorders and Treatments

Cited by 4,274

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 1,611

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 867

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 664

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 648

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology

Acute Myeloid Leukemia ResearchErythropoietin and Anemia Treatment

Cited by 292

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 183

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Adès, L., Girshova, L., Doronin, V. A., Díez-Campelo, M., Valcárcel, D., Kambhampati, S., Viniou, N.-A., Woszczyk, D., De Paz Arias, R., Symeonidis, A., et al. (2022) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 130

Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling

Rauner, M., Baschant, U., Roetto, A., Pellegrino, R. M., Rother, S., Salbach-Hirsch, J., Weidner, H., Hintze, V., Campbell, G., Petzold, A., et al. (2019) · Nature Metabolism

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 87

A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome

Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine

Acute Myeloid Leukemia ResearchIron Metabolism and Disorders

Cited by 85

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial

Wermke, M., Eckoldt, J., Götze, K. S., Klein, S. A., Bug, G., de Wreede, L. C., Kramer, M., Stölzel, F., von Bonin, M., Schetelig, J., et al. (2018) · The Lancet Haematology

Iron Metabolism and DisordersHematopoietic Stem Cell Transplantation

Cited by 59

Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome

Ribezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia

Acute Myeloid Leukemia ResearchBlood disorders and treatments

Cited by 51

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome

Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology

Acute Myeloid Leukemia ResearchProtein Degradation and Inhibitors

Cited by 42

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth

Petzer, V., Wermke, M., Tymoszuk, P., Wolf, D., Seifert, M., Ovaçin, R., Berger, S., Orth-Höller, D., Loacker, L., Weiss, G., et al. (2019) · Blood Advances

Antifungal resistance and susceptibilityIron Metabolism and Disorders

Cited by 22